To help families with a growth hormone deficiency (GHD) diagnosis, Teva has launched an updated web site (http://tevtropin.com/) that includes information specifically tailored for kids, teens and parents, and caregivers; instructional videos to help families learn about the Tjet® device; and information about Growth Solutions®, the company’s comprehensive patient support program that offers training and education, as well as insurance and reimbursement assistance.
“The Tjet® device is a great option for children with growth hormone deficiency, especially those who dislike needles,” states Paul Saenger, M.D. “The families in my practice have found that the Tjet® is a kid-friendly way to administer the daily medication that their children need to help reach their normal heights.”
As part of its commitment to pediatric patient care, Teva will also provide the Tjet® device and replacement supplies free of charge with all prescriptions for TEV-TROPIN® when requested by a physician.
The Tjet® device works by releasing a thin stream of TEV-TROPIN® that penetrates the stratum corneum (outermost layer skin) and is delivered into the subcutaneous (below the skin) tissue in two seconds through a tiny opening in the skin less than one third the size of a 30-gauge needle. With flexible dosing in increments of 0.05 mg, the Tjet® device delivers the prescribed dose of TEV-TROPIN® with one click of a button. The Tjet® device can be used on the back of the upper arm, the upper outer thigh, stomach, or buttocks. The Tjet® device has an eco-friendly design that means less waste compared to needle-pen devices or traditional syringe administration.
For more information about GHD and the Tjet® device, visit TEV-TROPIN
About Growth Hormone Deficiency
About TEV-TROPIN®
TEV-TROPIN® is indicated only for the treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone (GH).
Important Safety Information for TEV-TROPIN®
Growth hormone may be used in children with confirmed Prader-Willi Syndrome only when diagnosed with GHD. Children who are severely overweight, have breathing problems while awake or asleep, and have lung infections should stop use of growth hormone and consult a physician. This may occur more in boys.
Changes in eyesight, headaches, nausea, and vomiting may occur. Frequent eye examinations should be done before and during treatment. Patients should be observed for elevated blood glucose, underactive thyroid, underactive pituitary, skin cancers, development of a limp, or complaint of hip or knee pain. Patients with rapid onset critical illness as a result of open heart or abdominal surgery, multiple accidental trauma, or rapid onset respiratory failure should not be started on TEV-TROPIN®. Patients with injury or active cancer in the brain, eye problems related to diabetes, or bones that have stopped growing should not receive recombinant growth hormone.
When TEV-TROPIN® is administered at the same site over a long period of time, damage to the tissue may result. This can be avoided by rotating the injection site.
Because TEV-TROPIN® increases growth rate, patients with a history of curvature of the spine (scoliosis) should be monitored.
TEV-TROPIN® may interfere with other drugs removed from the body by the liver and careful monitoring is advisable.
The liquid provided to mix TEV-TROPIN® should not be used in newborns because of associated toxicity. Doses of reconstituted TEV-TROPIN® greater than 1 mL are not recommended. Consult your child's physician for doses greater than 1 mL. Do not exceed the dose recommended by your child's physician.
In studies of GHD children, headaches occurred infrequently. Injection-site reactions, for instance pain or bruising, occurred in 8 of the 164 treated patients.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80% of Teva's sales are in North America and Europe.
Please click here for full prescribing information.
TEV-TROPIN® and Tjet® are registered trademarks of Teva Pharmaceuticals USA.
Growth Solutions® is a registered service mark of Teva Pharmaceuticals USA.
Subscribe to our FREE Ezine and be eligible for Health News, discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
We videotape Press Conferences, produce Satellite MediaTour's, B-rolls, PSA's, - all with distribution: HealthyTelevisionProductions[email protected]